- Home
- CLLS vs CAES Comparison
CLLS vs CAES Comparison
Compare CLLS & CAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.89
Company Overview
Basic Information| Metric | CLLS | CAES |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 321.4M |
| IPO Year | 2014 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CLLS | CAES |
|---|---|---|
| Price | $1.89 | $10.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 19.1K | 16.1K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.35 | $10.05 |
| 52 Week High | $5.48 | $10.12 |
Technical Indicators
Market Signals| Indicator | CLLS | CAES |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 44.45 |
| Support Level | N/A | $10.06 |
| Resistance Level | $2.99 | $10.11 |
| Average True Range (ATR) | 0.18 | 0.01 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 8.77 | 0.00 |
Price Performance
Historical Comparison CLLS
CAES
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About CAES Cantor Equity Partners VII Inc. Class A Ordinary Shares
Cantor Equity Partners VII Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.